TRCT
ANTX icon

Tower Research Capital (TRC)’s AN2 Therapeutics ANTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.75K Buy
1,807
+1,233
+215% +$5.3K ﹤0.01% 4056
2026
Q1 		$1.96K Sell
574
-1,466
-72% -$3.03K ﹤0.01% 4569
2025
Q4 		$2.33K Sell
2,040
-88
-4% -$103 ﹤0.01% 4552
2025
Q3 		$2.7K Sell
2,128
-3,185
-60% -$3.64K ﹤0.01% 4594
2025
Q2 		$5.63K Buy
5,313
+3,231
+155% +$3.85K ﹤0.01% 4166
2025
Q1 		$2.83K Buy
2,082
+619
+42% +$779 ﹤0.01% 4499
2024
Q4 		$2.02K Sell
1,463
-2,793
-66% -$3.39K ﹤0.01% 4924
2024
Q3 		$4.55K Sell
4,256
-1,150
-21% -$2K ﹤0.01% 4503
2024
Q2 		$11.6K Buy
5,406
+4,293
+386% +$10.2K ﹤0.01% 4071
2024
Q1 		$3.62K Buy
1,113
+1,050
+1,667% +$11.4K ﹤0.01% 4827
2023
Q4 		$1.29K Sell
63
-2,982
-98% -$49.9K ﹤0.01% 5404
2023
Q3 		$49K Buy
+3,045
New +$34.5K ﹤0.01% 2565
2023
Q2 		– Sell
-2,797
Closed -$28K – 6023
2023
Q1 		$28K Buy
2,797
+1,941
+227% +$21.6K ﹤0.01% 3056
2022
Q4 		$8K Sell
856
-423
-33% -$5.66K ﹤0.01% 4361
2022
Q3 		$22K Sell
1,279
-3,083
-71% -$35.9K ﹤0.01% 3849
2022
Q2 		$34K Buy
4,362
+3,709
+568% +$49.1K ﹤0.01% 3237
2022
Q1 		$10K Buy
+653
New +$9.91K ﹤0.01% 4273

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Tower Research Capital (TRC)'s ANTX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its AN2 Therapeutics (ANTX) stake by 215% in Q2 2026, buying an estimated $5.3K and bringing the position to 1,807 shares worth $8.75K. The position accounts for ﹤0.01% of the portfolio, ranked #4056.

Tower Research Capital (TRC) first reported a position in ANTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $49K in Q3 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Tower Research Capital (TRC) held 1,807 shares of AN2 Therapeutics worth $8.75K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,233 AN2 Therapeutics shares in Q2 2026, an estimated $5.3K.
  • AN2 Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4056 holding.
  • Tower Research Capital (TRC) first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s AN2 Therapeutics position peaked at $49K in Q3 2023.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.